(MedPage Today) — CHICAGO — The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive metastatic breast cancer patients…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115827
Author :
Publish date : 2025-05-31 12:00:00
Copyright for syndicated content belongs to the linked Source.
